The combination of the anti-EGFR antibody cetuximab with irinotecan or the FOLFIRI regimen has improved treatment outcomes in RAS and BRAF wild-type metastatic colorectal cancers [46]. This evidence concerns the gene BRAF and metastatic colorectal cancer.